JP2009521215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521215A5 JP2009521215A5 JP2008547140A JP2008547140A JP2009521215A5 JP 2009521215 A5 JP2009521215 A5 JP 2009521215A5 JP 2008547140 A JP2008547140 A JP 2008547140A JP 2008547140 A JP2008547140 A JP 2008547140A JP 2009521215 A5 JP2009521215 A5 JP 2009521215A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- measuring
- prognostic
- detecting
- signature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 21
- 230000002068 genetic effect Effects 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 238000004393 prognosis Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 238000011529 RT qPCR Methods 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000013528 artificial neural network Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000007636 ensemble learning method Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000012880 independent component analysis Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000003012 network analysis Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000012706 support-vector machine Methods 0.000 claims 1
- 238000013517 stratification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ544432 | 2005-12-23 | ||
| NZ544432A NZ544432A (en) | 2005-12-23 | 2005-12-23 | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| PCT/NZ2006/000343 WO2007073220A1 (en) | 2005-12-23 | 2006-12-22 | Prognosis prediction for colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103714A Division JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009521215A JP2009521215A (ja) | 2009-06-04 |
| JP2009521215A5 true JP2009521215A5 (enExample) | 2013-01-10 |
| JP5632581B2 JP5632581B2 (ja) | 2014-11-26 |
Family
ID=38188869
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547140A Expired - Fee Related JP5632581B2 (ja) | 2005-12-23 | 2006-12-22 | 結腸直腸癌の予後予測 |
| JP2014103714A Expired - Fee Related JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
| JP2015257292A Expired - Fee Related JP6058780B2 (ja) | 2005-12-23 | 2015-12-28 | 結腸直腸癌の予後予測 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103714A Expired - Fee Related JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
| JP2015257292A Expired - Fee Related JP6058780B2 (ja) | 2005-12-23 | 2015-12-28 | 結腸直腸癌の予後予測 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10422005B2 (enExample) |
| EP (3) | EP1977237B1 (enExample) |
| JP (3) | JP5632581B2 (enExample) |
| KR (3) | KR101530689B1 (enExample) |
| CN (1) | CN101389957B (enExample) |
| AU (1) | AU2006328023B2 (enExample) |
| CA (2) | CA3015335A1 (enExample) |
| ES (3) | ES2536233T3 (enExample) |
| NZ (3) | NZ544432A (enExample) |
| WO (1) | WO2007073220A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2783348B1 (fr) * | 1998-09-15 | 2000-10-13 | Alstom Technology | Methode de discrimination entre un arc interne et un arc de coupure dans un disjoncteur de moyenne ou de haute tension |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| NZ593225A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis |
| US20100143902A1 (en) * | 2006-07-21 | 2010-06-10 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| DE102006035393A1 (de) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben |
| US20080234946A1 (en) * | 2007-03-22 | 2008-09-25 | University Of South Florida | Predictive radiosensitivity network model |
| US20090076734A1 (en) | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
| CA2688558A1 (en) * | 2007-06-04 | 2009-03-26 | Diagnoplex | Biomarker combinations for colorectal cancer |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| ES2332557B1 (es) | 2007-12-04 | 2011-02-02 | Universidad Autonoma De Madrid | Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal. |
| WO2010088672A1 (en) * | 2009-02-02 | 2010-08-05 | Rutgers, The State University Of New Jersey | Image-based risk score-a prognostic predictor of survival and outcome from digital histopathology |
| US10179936B2 (en) | 2009-05-01 | 2019-01-15 | Genomic Health, Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| EP2454596B1 (en) | 2009-07-16 | 2014-06-11 | Roche Diagnostics GmbH | Flap endonuclease-1 as a marker for cancer |
| US8445271B2 (en) | 2010-05-03 | 2013-05-21 | Enzo Life Sciences, Inc. | Processes and kits for determining multi-drug resistance of cells |
| WO2011140662A1 (en) * | 2010-05-13 | 2011-11-17 | The Royal Institution For The Advancement Of Learning / Mcgill University | Cux1 signature for determination of cancer clinical outcome |
| JP5916718B2 (ja) * | 2010-06-04 | 2016-05-11 | ビオメリューＢｉｏｍｅｒｉｅｕｘ | 結腸直腸癌の予後判定のための方法及びキット |
| US9539323B2 (en) | 2010-08-06 | 2017-01-10 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy |
| KR101401561B1 (ko) * | 2010-12-30 | 2014-06-11 | 주식회사 바이오인프라 | 복합 바이오마커를 활용한 암 진단 정보 생성 방법, 및 암 진단 예측 시스템 장치 |
| US20120184454A1 (en) * | 2011-01-14 | 2012-07-19 | Kalady Matthew F | Gene signature is associated with early stage rectal cancer recurrence |
| CN102183662A (zh) * | 2011-03-22 | 2011-09-14 | 浙江大学 | 一种大肠癌预后预测模型的建立方法 |
| CN104053788A (zh) * | 2011-11-28 | 2014-09-17 | 加泰罗尼亚调查和高级研究机构 | 结肠直肠癌的预后方法和试剂盒 |
| US9977033B2 (en) * | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| KR20160045547A (ko) | 2014-10-17 | 2016-04-27 | 에스케이텔레콤 주식회사 | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| US11335463B2 (en) | 2016-02-02 | 2022-05-17 | Guardant Health, Inc. | Cancer evolution detection and diagnostic |
| WO2017143322A1 (en) * | 2016-02-18 | 2017-08-24 | University Of South Florida | Materials and methods for detecting cancer based on urinary levels of rhamm |
| KR102584661B1 (ko) | 2016-05-10 | 2023-10-04 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 염증 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약 및 진단 방법 |
| US10360499B2 (en) * | 2017-02-28 | 2019-07-23 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US9934364B1 (en) | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US11164082B2 (en) | 2017-02-28 | 2021-11-02 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US11984200B2 (en) * | 2017-06-13 | 2024-05-14 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| KR102715821B1 (ko) * | 2017-11-09 | 2024-10-10 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법 |
| WO2019154884A1 (en) * | 2018-02-07 | 2019-08-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for determining cancer invasiveness and patient prognosis |
| WO2019173233A1 (en) * | 2018-03-05 | 2019-09-12 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| TW202018727A (zh) | 2018-11-09 | 2020-05-16 | 財團法人工業技術研究院 | 整體式學習預測方法與系統 |
| CN111321221B (zh) * | 2018-12-14 | 2022-09-23 | 中国医学科学院肿瘤医院 | 用于预测直肠癌局部切除手术后复发风险的组合物、微阵列和计算机系统 |
| CN109599181B (zh) * | 2019-01-09 | 2021-04-16 | 中国医学科学院肿瘤医院 | 一种在治疗前针对t3-larc患者的生存预测系统及预测方法 |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| CN109762907B (zh) * | 2019-03-27 | 2022-02-22 | 中山大学附属第六医院 | 缺氧相关基因在预测i/ii期结直肠癌的试剂盒中的应用 |
| CN109811057B (zh) * | 2019-03-27 | 2022-02-22 | 中山大学附属第六医院 | 缺氧相关基因在结直肠癌预测系统中的应用 |
| US11154240B2 (en) | 2019-04-02 | 2021-10-26 | Kpn Innovations Llc | Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance |
| CN110246591B (zh) * | 2019-07-15 | 2021-11-05 | 中国中医科学院西苑医院 | 一种中医药治疗人群的预后预测系统 |
| CN112342295A (zh) * | 2019-08-06 | 2021-02-09 | 中山大学孙逸仙纪念医院 | 一种检测人结直肠癌的肿瘤标志物及其应用 |
| CN110791565B (zh) * | 2019-09-29 | 2021-09-03 | 浙江大学 | 一种用于ii期结直肠癌复发预测的预后标记基因及随机生存森林模型 |
| WO2021119761A1 (en) | 2019-12-20 | 2021-06-24 | Hudson Institute of Medical Research | Cxcl10 binding proteins and uses thereof |
| US12020417B2 (en) * | 2020-04-24 | 2024-06-25 | Camtek Ltd. | Method and system for classifying defects in wafer using wafer-defect images, based on deep learning |
| US11289206B2 (en) | 2020-06-02 | 2022-03-29 | Kpn Innovations, Llc. | Artificial intelligence methods and systems for constitutional analysis using objective functions |
| US12176108B2 (en) | 2020-06-02 | 2024-12-24 | Kpn Innovations Llc | Artificial intelligence methods and systems for constitutional analysis using objective functions |
| US11211158B1 (en) | 2020-08-31 | 2021-12-28 | Kpn Innovations, Llc. | System and method for representing an arranged list of provider aliment possibilities |
| CN112301131B (zh) * | 2020-11-13 | 2021-10-26 | 中国医学科学院基础医学研究所 | Rnf138作为预测结直肠癌对sc75741治疗敏感性的生物标志物的应用 |
| CN113591919B (zh) * | 2021-06-29 | 2023-07-21 | 复旦大学附属中山医院 | 基于ai对早期肝细胞癌术后复发预后的分析方法及系统 |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| CN114652814B (zh) * | 2022-03-11 | 2023-02-03 | 郑州大学第一附属医院 | 一种免疫检查点抑制剂及应用 |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| US20240028964A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| WO2024138106A1 (en) * | 2022-12-23 | 2024-06-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for identification of hypomorphic p53 variants |
| CN115938590B (zh) * | 2023-02-09 | 2023-05-02 | 四川大学华西医院 | 结直肠癌术后lars预测模型的构建方法及预测系统 |
| CN117947166B (zh) * | 2024-01-30 | 2025-08-29 | 复旦大学附属肿瘤医院 | 用于肠癌预后的标志物组、产品、系统及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| GB9805918D0 (en) * | 1998-03-19 | 1998-05-13 | Nycomed Amersham Plc | Sequencing by hybridisation |
| AU3755300A (en) * | 1999-03-15 | 2000-10-04 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| AU2001278900A1 (en) | 2000-07-18 | 2002-01-30 | Kvh Industries, Inc. | Method of incorporating optical material into an optical fiber |
| US20030077568A1 (en) * | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| AU2002252144A1 (en) * | 2001-02-27 | 2002-09-12 | Case Western Reserve University | Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| CA2526878A1 (en) * | 2003-04-08 | 2004-10-21 | Colotech A/S | A method for detection of colorectal cancer in human samples |
| JP2007516693A (ja) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
| US20050048494A1 (en) * | 2003-08-28 | 2005-03-03 | Yixin Wang | Colorectal cancer prognostics |
| EP1704248B1 (en) * | 2003-12-27 | 2010-05-05 | Aros Applied Biotechnology A/S | Classification of colon cancer |
-
2005
- 2005-12-23 NZ NZ544432A patent/NZ544432A/en unknown
-
2006
- 2006-12-22 EP EP06835771.4A patent/EP1977237B1/en not_active Not-in-force
- 2006-12-22 NZ NZ597363A patent/NZ597363A/xx unknown
- 2006-12-22 ES ES11172587.5T patent/ES2536233T3/es active Active
- 2006-12-22 JP JP2008547140A patent/JP5632581B2/ja not_active Expired - Fee Related
- 2006-12-22 ES ES06835771.4T patent/ES2525219T3/es active Active
- 2006-12-22 CA CA3015335A patent/CA3015335A1/en not_active Abandoned
- 2006-12-22 ES ES11172410.0T patent/ES2484702T3/es active Active
- 2006-12-22 KR KR1020137023872A patent/KR101530689B1/ko not_active Expired - Fee Related
- 2006-12-22 WO PCT/NZ2006/000343 patent/WO2007073220A1/en not_active Ceased
- 2006-12-22 NZ NZ586616A patent/NZ586616A/en unknown
- 2006-12-22 EP EP11172587.5A patent/EP2392678B1/en not_active Not-in-force
- 2006-12-22 KR KR1020147036584A patent/KR101579934B1/ko not_active Expired - Fee Related
- 2006-12-22 CA CA2640352A patent/CA2640352C/en not_active Expired - Fee Related
- 2006-12-22 KR KR1020087018020A patent/KR101562644B1/ko not_active Expired - Fee Related
- 2006-12-22 EP EP11172410.0A patent/EP2371972B1/en not_active Not-in-force
- 2006-12-22 AU AU2006328023A patent/AU2006328023B2/en not_active Ceased
- 2006-12-22 CN CN2006800529023A patent/CN101389957B/zh not_active Expired - Fee Related
-
2008
- 2008-06-20 US US12/214,782 patent/US10422005B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 JP JP2014103714A patent/JP6218141B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-21 US US14/860,024 patent/US20160068916A1/en not_active Abandoned
- 2015-12-28 JP JP2015257292A patent/JP6058780B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-27 US US16/552,737 patent/US11180815B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521215A5 (enExample) | ||
| O'Brien et al. | CENP‐F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer | |
| Campone et al. | Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen | |
| Zhou et al. | Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue | |
| CN103097548A (zh) | 基于多癌症侵袭相关机制的生物标记 | |
| JP2011526693A (ja) | 転移に関連する徴候および決定因子、ならびにそれらの使用方法 | |
| JP2015536667A (ja) | 癌のための分子診断検査 | |
| CN103038642B (zh) | 方法、阵列及其用途 | |
| US20230047712A1 (en) | Methods of Treatments Based Upon Molecular Response to Treatment | |
| JP2022505295A (ja) | ヒト腫瘍のがん細胞における分子活性を定量化するための方法 | |
| Yaghoobi et al. | Advances in quantitative immunohistochemistry and their contribution to breast cancer | |
| Jiang et al. | Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression | |
| Haq et al. | Identification of specific biomarkers for anaplastic thyroid carcinoma through spatial transcriptomic and immunohistochemical profiling | |
| Ozcan | PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2-breast cancer | |
| Zhang et al. | A systems biology-based classifier for hepatocellular carcinoma diagnosis | |
| JP2016519767A5 (enExample) | ||
| Herold et al. | Biosensors and molecular technologies for cancer diagnostics | |
| Niu et al. | Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics | |
| CN113444796B (zh) | 与肺癌相关的生物标志物及其在诊断癌症中的应用 | |
| Theile et al. | Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma | |
| JP2006508326A5 (enExample) | ||
| Wang et al. | Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection | |
| Maschietto et al. | Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour | |
| KR20190012715A (ko) | Park7, apex1 및 s1pr1 단백질을 포함하는 혈관질환 진단용 바이오마커 | |
| US20160047000A1 (en) | Methods and systems for treatment of ovarian cancer |